Takada K, Palm C A, Epstein S E, Cowgill L D
William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA.
The Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA.
J Vet Intern Med. 2018 Mar;32(2):722-726. doi: 10.1111/jvim.15047. Epub 2018 Feb 22.
Renal replacement therapies can be life-saving for dogs with severe acute kidney injury (AKI), however, comorbidities including pancreatitis might affect outcome.
HYPOTHESIS/OBJECTIVES: To investigate the prevalence of pancreas-specific lipase (Spec cPL) measurements consistent with pancreatitis (≥400 μg/L) in dogs undergoing intermittent hemodialysis (IHD) for treatment of AKI and to determine whether there were associations between 30-days outcomes and Spec cPL measurements.
Fifty-three client-owned dogs presented to teaching hospitals between November 2008 and September 2016 that underwent IHD.
Retrospective medical record review from dogs that received IHD for management of AKI and also had a Spec cPL measurement. Association between survival, dialysis-dependency, and Spec cPL measurements was assessed.
Forty of 53 (76%) dogs were alive at 30-days and 33/53(62%) had a Spec cPL result ≥400 μg/L. Spec cPL was not significantly different either between surviving (635.5 μg/L, range 29-1,001) and nonsurviving dogs (860 μg/L, range 56-1,001; P = 0.75) or between dialysis-dependent (1,001 μg/L, range 177-1,001) and nondialysis-dependent dogs (520 μg/L, range 29-1,001; P = 0.08). Spec cPL ≥400 μg/L was not significantly associated either with survival (P = 0.74) or dialysis-dependency (P = 0.33).
Results revealed a high prevalence of Spec cPL ≥400 μg/L in dogs with AKI treated with IHD. No significant associations between Spec cPL and survival or dialysis-dependency in dogs with AKI at 30 days were identified in the current study, however, the latter could be due to lack of power in this study.
肾脏替代疗法对患有严重急性肾损伤（AKI）的犬类可能具有挽救生命的作用，然而，包括胰腺炎在内的合并症可能会影响治疗结果。
假设/目的：调查接受间歇性血液透析（IHD）治疗AKI的犬类中，胰腺特异性脂肪酶（Spec cPL）测量值符合胰腺炎标准（≥400μg/L）的患病率，并确定30天治疗结果与Spec cPL测量值之间是否存在关联。
2008年11月至2016年9月间到教学医院就诊并接受IHD的53只客户拥有的犬类。
对因AKI接受IHD治疗且进行了Spec cPL测量的犬类进行回顾性病历审查。评估生存、透析依赖与Spec cPL测量值之间的关联。
53只犬中有40只（76%）在30天时存活，33/53（62%）的Spec cPL结果≥400μg/L。存活犬（635.5μg/L，范围29 - 1,001）与非存活犬（860μg/L，范围56 - 1,001；P = 0.75）之间，以及透析依赖犬（1,001μg/L，范围177 - 1,001）与非透析依赖犬（520μg/L，范围29 - 1,001；P = 0.08）之间的Spec cPL无显著差异。Spec cPL≥400μg/L与生存（P = 0.74）或透析依赖（P = 0.33）均无显著关联。
结果显示，接受IHD治疗的AKI犬类中，Spec cPL≥400μg/L的患病率较高。在本研究中，未发现Spec cPL与AKI犬类30天时的生存或透析依赖之间存在显著关联，不过，后者可能是由于本研究的样本量不足。
